hrp0094p2-115 | Diabetes and insulin | ESPE2021

HbA1c and Glucose Management Indicator relationship: can HbA1c determination be avoided?

Navarro Moreno Constanza , Sanchez Ruiz Daniel , Jose Garcia Garcia Emilio , Elizagarate Izaskun Marchueta , Gomez Gila Ana Lucia ,

Introduction: Continuous Glucose Monitoring (CGM) devices have introduced new metrics to assess metabolic situation of patients with type 1 diabetes mellitus (T1DM). Among them, the glucose management indicator (GMI) provides a proxy to HbA1c, however, these measures do not always match.Purposes: To evaluate the concordance between GMI and HbA1c, and determinate in which scenarios GMI could replace HbA1c.Subjects a...

hrp0082pl4 | Gene Therapy | ESPE2014

Gene Therapy

Aubourg P

Background: X-linked adrenoleukodystrophy (X-ALD) presents with two phenotypes: i) an adult form (adrenomyeloneuropathy, AMN), that involves axonal tracts without demyelination within the spinal cord and affects adult males and more than 80% of X-ALD heterozygote women in adulthood resulting in severe paraplegia. This far the most frequent form of X-ALD. Addison’s disease is very rare in X-ALD women but frequent in adult AMN males, very often with onset years or decades b...

hrp0086p2-p769 | Pituitary and Neuroendocrinology P2 | ESPE2016

Novel Uses of Psychiatric Drugs to Treat Hypothalamic Obesity

Julian Maria Cristina Azcona San , Gomez-Cardenas Francisco Javier Aguilar , Falconi Jose Luis Leon , Elicegui Amaia Ochotorena , de las Heras Ana Navedo , Lamban Ana Catalan , Martin Patricia Sierrasesumaga , de Almiron Monica Prados Ruiz , Martin Eduardo Arnaus

Background: Hypothalamic obesity (HyOb) is a disease characterized by weight gain resistant to lifestyle changes and dietary restriction. The main clinical findings are hyperfagia and decline of satiety, high levels of insulin and an increase of adipogenesis. The major problem for these patients is that conventional treatments, either medical or surgical are not succesful and have variable results.Objective and hypotheses: We aim to describe the natural ...

hrp0084p2-427 | GH & IGF | ESPE2015

rhGH Replacement Therapy Ameliorates Body Composition Substantially but has No Effect in the Quality of Life in Adolescents with GH deficiency – A Cross-Sectional Study

Stefanaki Charikleia , Paltoglou George , Bacopoulou Flora , Boschiero Dario , Chrousos George P

Background: GH is fundamental in skeletal growth during puberty, however detailed studies of body composition analyses in adolescents with GH deficiency on GH therapy are scarce. Moreover, there are few studies on the psychologic aspects of hrGH therapy in this population.Objective and hypotheses: In this case-control study, we investigated differences in body composition based on bio-impedance measurements between adolescents with idiopathic GH deficien...

hrp0095p2-152 | GH and IGFs | ESPE2022

IGF1 as reassessment method of GH deficiency in adulthood

Belen Ariza-Jimenez Ana , Antonio Ariza-Jimenez Jose , Jose Martinez-Aedo Ollero Maria , Pedro Lopez-Siguero Juan

Background: GH deficiency may not persist into adulthood. Thus, it is recommended to reassess it after reaching adult height. However, according to stimulation tests, they have poor specificity, reproducibility, and poor standardization of hormonal measurement, and they are expensive and involve risks.Objective and hypotheses: Establish if IGF1 would be a better reassessing method than stimulation tests in adult GH defic...

hrp0092p3-283 | Late Breaking Abstracts | ESPE2019

Comparison of Densitometric Aspects during the Transition Period in Patients with Congenital and Acquired Pituitary Deficiency: First Argentine Experience

Boquete Hugo , Boquete Carla , Ruibal Gabriela , Suarez Martha , Azaretzky Miriam , Nuñez Chavarria Eleonora , Sequera Ana , Fideleff Hugo

The transition phase is the period from the end of puberty until achievement of full adult maturity. We report the results from 45 patients with pituitary deficiency (15-24.9years), 28 (16males) with congenital insufficiency (G1) and 17 (10males) with acquired disease (G2), evaluated at the end of GH therapy. All cases had confirmed GH deficiency; 89.2 % of cases from G1 had multiple pituitary deficiencies (TSH 23/28, LH/FSH 19/28, ACTH 15/28 and Prolactin 3/28), 94.1 &#37...

hrp0097p1-176 | Sex Differentiation, Gonads and Gynaecology, and Sex Endocrinology | ESPE2023

Mechanism of mutagenesis and phenotype implications of small indels in the Androgen Receptor gene in Androgen Insensitivity Syndrome

Loch Batista Rafael , Ramos Raquel , Caroline Afonso Ana , Petroli Reginaldo , Tereza Ferrari Maria , Domenice Sorahia , Nishi Mirian , Mendonca Berenice

Indels are highly abundant in human genomes and have contributed massively to genome evolution. However, the role of indels and their underlined mechanisms of mutagenesis in Mendelian disorders still needs to be appreciated. To explore the contribution of indels in a monogenic disorder, we analyzed all indels already described in the AR gene, including three novel indels found in our cohort. We analyzed the indel distribution through the AR coding region, compared wit...

hrp0097p2-44 | Sex Differentiation, Gonads and Gynaecology, and Sex Endocrinology | ESPE2023

New variant in DHX37 associated to 46,XY gonadal dysgenesis

Dominguez-Riscart Jesus , Garcia-Zarzuela Ana , Arellano-Ruiz Paola , Benito-Sanz Sara , Delgado-Cotan Lourdes , Maria Lechuga-Sancho Alfonso

Introduction: 46,XY gonadal dysgenesis (GD) represents a heterogeneous group of disorders/differences of sex development (DSD) characterized by abnormal gonadal development leading to a wide phenotypic spectrum. Variable degrees of external genitalia undervirilization are observed, ranging from micropenis to female-like genitalia and partially or fully-developed Mullerian derivatives.Case Report: A 6 years-old boy follow...

hrp0084p2-406 | GH & IGF | ESPE2015

Metabolic Health in Short Children Born Small for Gestational Age Treated with GH and GnRHa: Results of a Randomised, Dose-response Trial

van der Steen M , Lem A J , van der Kaay D C M , Waarde W M Bakker-van , van der Hulst F J P C M , Neijens F S , Noordam C , Odink R J , Oostdijk W , Schroor E J , Sulkers E J , Westerlaken C , Hokken-Koelega A C S

Background: Previously we showed that pubertal children born small for gestational age (SGA) with a poor adult height (AH) expectation can benefit from treatment with GH 1 mg/m2 per day (~0.033 mg/kg per day) in combination with 2 years of GnRH analogue (GnRHa) and even more so with a double GH dose. GnRHa treatment is thought to have negative effects on body composition and blood pressure. Long-term effects and GH-dose effects on metabolic health in children treate...